OOIR: Observatory of International Research

Papers

(The TQCC of Hematology-American Society of Hematology Education Program is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Relapsed disease: off-the-shelf immunotherapies vs customized engineered products	57
Clots in unusual places: lots of stress, limited data, critical decisions	54
The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally	49
Acute GVHD: think before you treat	34
Provoked vs minimally provoked vs unprovoked VTE: does it matter?	33
Thrombocytopenia in pregnancy	31
How do we optimally utilize factor concentrates in persons with hemophilia?	31
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease	29
Recognizing, defining, and managing CAR-T hematologic toxicities	27
Optimal approach to T-cell ALL	25
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?	24
The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy	24
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?	23
What factors guide treatment selection in mycosis fungoides and Sezary syndrome?	22
Hematopoietic cell transplantation for sickle cell disease: updates and future directions	21
Controversies in the management of early-stage Hodgkin lymphoma	21
Diagnosis and therapeutic decision-making for the neutropenic patient	21
Mastocytosis demystified	21
Evidence-Based Minireview: Strategies to manage a severely HLA-alloimmunized patient with refractory thrombocytopenia	20
Evidence-Based Minireview: Clinical utilization of panel-based molecular testing for patients with AML	18
The dos, don'ts, and nuances of thrombophilia testing	18
Dual-targeted regimens for the frontline treatment of CLL	17
Relapsed ALL: CAR T vs transplant vs novel therapies	17
Bispecific antibody therapies	17
Lifelong TKI therapy: how to manage cardiovascular and other risks	17

AL amyloidosis: untangling new therapies	17
Modern management of Fanconi anemia	16
Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies	16
Cytoreduction for ET and PV: who, what, when, and how?	16
Labor and delivery: DIC, HELLP, preeclampsia	16
Evidence-Based Minireview: For overweight or obese persons with hemophilia A, should factor VIII dosing be based on ideal or actual body weight?	16
Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia	16
What have we learned about the patient's experience of von Willebrand disease? A focus on women	16
Biology of follicular lymphoma: insights and windows of clinical opportunity	16
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease	16
Management of Fanconi anemia beyond childhood	15
Quantifying menorrhagia and overview of nonsurgical management of heavy menstrual bleeding	15
Burnett AE, Ragheb B, Kaatz S. Perioperative consultative hematology: can you clear my patient for a procedure? Hematology Am Soc Hematol Educ Program. 2021;2021:521-528.	15
Intravenous iron therapy in pediatrics: who should get it and when is the right time?	15
Novel platelet products including cold-stored platelets	15
Treatment of VTE in the thrombocytopenic cancer patient	14
Your chemo is no good here: management of high-risk MCL	14
Novel conditioning and prophylaxis regimens for relapse prevention	14
New definitions for antiphospholipid syndrome: ready for clinical use?	13
Neurological manifestations of MGUS	13
Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease	13
The POD24 challenge: where do we go from here for early progressors?	13
Risk-stratification in frontline CLL therapy: standard of care	13
Mutations and MRD: clinical implications of clonal ontogeny	13
On the horizon: upcoming new agents for the management of ITP	13
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?	13
Gene therapy for hemophilia	12
Pegylated interferon: the who, why, and how	12
Anticoagulation at the end of life: whether, when, and how to treat	12
To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients	12
Diagnosis and management of hereditary hemochromatosis: lifestyle modification, phlebotomy, and blood donation	12
Novel immunotherapies in the treatment of AML: is there hope?	11
Inpatient recognition and management of HLH	11
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	11
Dyskeratosis congenita and telomere biology disorders	11
Diagnostic pitfalls and conundrums in type 1 von Willebrand disease	10
Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing	10
Has PD-1 blockade changed the standard of care for cHL?	10
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma	10
Managing pregnancy in patients with sickle cell disease from a transfusion perspective	10
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL	10
Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept	10
Targeted medical therapies for vascular anomalies	9
What is the ideal approach—doublet, triplet, or quadruplet(s)?	9
Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy	9
Challenges in hospice and end-of-life care in the transfusion-dependent patient	9
Large granular lymphocyte leukemia: a clonal disorder with autoimmune manifestations	9
Updates on strategies to integrate palliative care in hematologic malignancy	9
Givosiran: a targeted treatment for acute intermittent porphyria	9
In pursuit of a functional cure for follicular lymphoma	9

Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies	9
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient	8
What makes a pediatric or young adult patient an appropriate transplant candidate?	8
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma	8
Biology of post-transplant relapse: actionable features	8
Pregnancy in special populations: challenges and solutions practical aspects of managing von Willebrand disease in pregnancy	8
Modified T cells as therapeutic agents	8
Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?	8
Have we reached a molecular era in myelodysplastic syndromes?	8
Options at the time of relapse after anti-BCMA therapy	7
Using disease-modifying therapies in sickle cell disease	7
Multiple myeloma: a paradigm for blending community and academic care	7
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?	7
Resistance mutations in CML and how we approach them	7
Amyloid consults do not have to be vexing	7
Pyruvate kinase activators for treatment of pyruvate kinase deficiency	7
Evidence-Based Minireview: In young children with severe sickle cell disease, do the benefits of HLA-identical sibling donor HCT outweigh the risks?	7
How to avoid early mortality in acute promyelocytic leukemia	7
Molecular prognostication in Ph-negative MPNs in 2022	7
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease	7
Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia	7
T-cell lymphopenia in frequent volunteer platelet donors	7
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	7
Upfront therapy: the case for continuous treatment	7
Clinical manifestations of telomere biology disorders in adults	7
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations	7
Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma	7
Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy	7
Novel approaches to acute graft-versus-host disease prevention	7
Passive immune therapies: another tool against COVID-19	7